Lakefront Biotherapeutics NV (LKFT)
- Sector
- Biotechnology
- Last price
- $34.39
- As of
Kresmion compiles this page from LKFT's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Lakefront Biotherapeutics NV (LKFT): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-11-16.
See the full LKFT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for LKFT on one page. Preview it with sample data, then open it live with a free account.
Preview the LKFT dossierActive events for LKFT
- mediumEarnings above estimates
Q3-2026: Beat consensus by 90.9%, EPS $-0.04 vs $-0.4386 estimate
- mediumEarnings above estimates
Q2-2026: Beat consensus by 106.8%, EPS $0.03 vs $-0.4386 estimate
- high13F: funds added
3 tracked funds increased LKFT this 2026Q2, institutional consensus
- high13F: large increase
CITADEL ADVISORS LLC added +1511% to LKFT (2026Q2)
- high13F: large increase
MILLENNIUM MANAGEMENT LLC added +68% to LKFT (2026Q2)
FREE, NO ACCOUNT
Every event on LKFT, as it fires
You are seeing 5 of 10 events recorded on LKFT since 2026-05-26.
The five above landed across 3 days. The other 5 were recorded on 1 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
LKFT positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 36315X101 · 2026Q3 | $12.6M | 0.02% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, LKFT
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
More data on LKFT
LKFT against its peers
LKFT's operating margin of 26.5% ranks in the 83rd percentile of 14 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | LKFT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.1B EUR | n/a | n/a | 0 |
| Revenue YoY | 303.5% | n/a | n/a | 0 |
| Gross margin | 97.3% | 87.7% | 79 | 6 |
| Operating margin | 26.5% | -508.2% | 83 | 14 |
| Net margin | 28.9% | -435.2% | 83 | 14 |
| Return on equity | 9.9% | -36.9% | 93 | 19 |
| 1 year | 14.1% | 4.7% | 60 | 20 |
Peers (20): BHVN, ZYME, VERA, CLDX, IMNM, AUPH, REPL, RXRX, NAMS, SEPN, VCYT, BCRX, MAZE, PHVS, AGIO, ZBIO, PVLA, RCUS, MBX, STOK. Left out: ZLDPF (no annual filing), TRAX (no annual filing), COAG (no annual filing), GENB (no annual filing), KLRA (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (LKFT: 20-F), reported in EUR. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in LKFT on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on LKFT in the last 180 days.
Upstream: SEC EDGAR filings for LKFT
Kresmion, "Lakefront Biotherapeutics NV (LKFT) institutional holdings and SEC filings", data as of 2026-11-16, https://kresmion.com/research/LKFT. Upstream data: SEC EDGAR filings for LKFT.
Link to this data (HTML):
<a href="https://kresmion.com/research/LKFT">Lakefront Biotherapeutics NV (LKFT) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow LKFT on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to LKFT for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.